Prednisolone

Generic Name: Prednisolone

Brand Names: Millipred Dp 6 Day

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₈O_₅

CAS Number: 50-24-8

Unique Ingredient Identifier: 9PHQ9Y1OLM

Background: Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Prednisolone was granted FDA approval on 21 June 1955.

Indication: Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: -

Clinical Trials

CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study

Phase 2

Conditions: Peripheral T-cell Lymphoma NOS
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Hepatosplenic Gamma/ Delta T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma

Interventions: Drug: Gemcitabine
Drug: Cyclophosphamide
Drug: methylprednisolone
Drug: Doxorubicin
Drug: Vincristine
Drug: Cisplatin
Drug: Prednisolone

First Posted Date: 2012-11-01

Last Posted Date: 2018-03-15

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 87

Registration Number: NCT01719835

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust - London and Surrey, London, United Kingdom

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Prednisolone

First Posted Date: 2012-09-17

Last Posted Date: 2019-03-15

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 82

Registration Number: NCT01685983

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Phase 2

Completed

Conditions: Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Prednisolone
Drug: Rituximab
Drug: Inotuzumab Ozogamicin
Drug: Gemcitabine

First Posted Date: 2012-09-05

Last Posted Date: 2022-05-18

Lead Sponsor: University College, London

Target Recruit Count: 129

Registration Number: NCT01679119

Locations: 🇬🇧
North Hampshire Hospital, Basingstoke, United Kingdom
🇬🇧
West Suffolk Hospital, Bury St Edmunds, United Kingdom
🇬🇧
University Hospital, Coventry, Coventry, United Kingdom

and more 37 locations

Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis

Phase 2

Completed

Conditions: Allergic Bronchopulmonary Aspergillosis

Interventions: Drug: Prednisolone
Drug: Voriconazole

First Posted Date: 2012-06-18

Last Posted Date: 2017-12-12

Lead Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Target Recruit Count: 50

Registration Number: NCT01621321

Locations: 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India

Prednisolone for Pain Reduction in Knee OA

Phase 4

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Prednisolone

First Posted Date: 2012-06-14

Last Posted Date: 2012-06-14

Lead Sponsor: University of Alexandria

Target Recruit Count: 125

Registration Number: NCT01619163

Locations: 🇪🇬
Faculty of Medicine, University of Alexandria, Alexandria, Egypt

Steroid Withdrawal Immunosuppression After Renal Transplantation

Phase 4

Conditions: Disorder Related to Renal Transplantation

Interventions: Drug: Prednisolone

First Posted Date: 2012-03-12

Last Posted Date: 2012-03-12

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 30

Registration Number: NCT01550445

Locations: 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of

Velcade (Bortezomib) Consolidation After Transplant

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Thalidomide
Drug: Cyclophosphamide
Drug: Prednisolone
Drug: Dexamethasone

First Posted Date: 2012-02-27

Last Posted Date: 2018-12-27

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 256

Registration Number: NCT01539083

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone
Drug: Placebo
Drug: Ipatasertib
Drug: Apitolisib
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2011-12-06

Last Posted Date: 2023-09-14

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 298

Registration Number: NCT01485861

Locations: 🇺🇸
HonorHealth Research Institute ? Bisgrove, Scottsdale, Arizona, United States
🇺🇸
Kaiser Permanente Medical Ctr, Honolulu, Hawaii, United States
🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia

and more 56 locations